SCHEMBL4366241

SCHEMBL4366241

O=Cc1ccccc1Oc1cccnc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.66
GAA P10253 1/20 0.66
KMT2A Q03164 1/20 0.66
ALDH1A1 P00352 6/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
NPSR1 Q6W5P4 1/20 0.53
TDP1 Q9NUW8 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.47
HTT P42858 3/20 0.46
HPGD P15428 2/20 0.46
CYP19A1 P11511 2/20 0.43
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
ORAI1 Q96D31 1/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
SRC P12931 1/20 0.41
GRM5 P41594 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2540885 0.81 LMNA (0.72) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL3950719 0.80 LMNA (0.46) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL29361707 0.80 LMNA (1.00) LMNAGAAKMT2AALDH1A1CYP1A2
Benzene SCHEMBL27888748 0.80 LMNA (1.00) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL95238 0.80 LMNA (1.00) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL7371098 0.79 LMNA (0.47) LMNAGAAKMT2AALDH1A1TDP1
SCHEMBL2511336 0.78 LMNA (0.62) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL31599176 0.78 LMNA (0.88) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL8827677 0.78 ALDH1A1 (0.59) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL31241187 0.77 LMNA (0.92) LMNAGAAKMT2AALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482340-B2 Pyridine derivatives useful for inhibiting sodium/calcium exchange system ORION CORPORATION (FI) 2009-01-27 US disclosed
WO-2007079173-A2 NOVEL 2-HETEROARYLOXY-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS EMERGENT BIOSOLUTIONS INC. (US) 2007-07-12 WO disclosed
US-20060241147-A1 Pyridine derivatives useful for inhibiting sodium/calcium exchange system ORION CORPORATION (FI) 2006-10-26 US disclosed
EP-1583759-A1 PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM ORION CORPORATION (FI) 2005-10-12 EP disclosed
WO-2004063191-A1 PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM ORION CORPORATION (FI) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241147-A1 Pyridine derivatives useful for inhibiting sodium/calcium exchange system SLC8B1, CACNA1A, MCU LMNA 4227/4885GAA 1772/4885KMT2A 4533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.